Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery – it is attracting partner and investor interest.
CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector manufacturing. Plus, he shares an update on the company’s fundraising, partnering, and wholly owned programs.
